ABSTRACT
have the potential to act as surrogate antibodies in a number of applications in cytokine quantification and purification and could be potentially useful reagents to complement the existing panel of anti-cytokine, monoclonal, polyclonal, or engineered antibodies that are currently available.

CYTOKINE DETECTION METHODOLOGIES
Cytokines are soluble protein mediators of immune function that are pivotal to a balanced innate or cell-mediated immune response. Since cytokine levels can be indicative of disease progression and/or resolution, and in a growing number of situations cytokines are being evaluated as therapeutics, there is a common need in both basic and applied research to purify and/or to measure key cytokines rapidly with accuracy, precision, sensitivity, and at low cost. Table 1 summarizes the current methods for measuring cytokine levels.
Efficient methods for monitoring cytokine levels will facilitate the diagnosis and/or treatment of many disease states, and thus will be critical to the efficient clinical delivery of medicine. The need for reliable, extremely rapid (<45 min) cytokine assays is well recognized. Currently, the assay systems based on antibodies have encountered problems with specificity, reproducibility, and assay time. Novel methods to quantify and purify cytokines are expected to expand as molecular medicine becomes a more refined science.
Cytokine mRNA Measurements
Cytokine levels can be estimated by measuring the cellular cytokine mRNA levels by either ribonuclease protection or RT PCR-based assays. Both assays are able to simultaneously analyze RNA levels for multiple cytokines in cell extracts. These RNA-based assays are very labor intensive, extremely sensitive to variations in experimental conditions (e.g., the presence of RNases), and are time consuming. Another major drawback is the lack of an absolute correlation between the levels of cytokine mRNA and protein. This is especially true with the measurement of cytokine levels in serum where tissue fixed cells may contribute to the circulating cytokine, but their cytokine mRNA would be absent from peripheral blood lymphocytes specimens.
Bioassay
The first bioassays were based on primary cells taken directly from the hematopoietic/immune system; however, difficulties in purifying the responding cells to homogeneity and large standard deviations among assays using different donors affected their utility. The availability of continuously growing cell lines that were responsive to cytokines and the development of receptor-transfected cell lines have permitted the development of more specific assays that are easier to perform and allow the measurement of the levels of biologically active cytokines in various DRUG DISCOVERY BioTechniques 32:160-171 (January 2002) samples. The cell response to the cytokine of choice can be measured in a number of ways, including proliferation, anti-proliferation, cytotoxicity, chemotaxis, inhibition of virus cytopathic effect, and the induction of secondary molecules including cell surface or secreted proteins (46) . The major strength of the bioassay is that it provides estimates of biologically active cytokines, whereas immunoassays measure both biologically active and inactive cytokines. The bioassay, however, has a number of shortcomings. The assay can show sensitivity to nonspecific inhibition that is due to serum proteins in the sample. Also, the responding cell is usually sensitive to multiple cytokines requiring the inclusion of specific antibodies to the cytokine of interest to provide the necessary assay specificity. Furthermore, most bioassays require at least 24 h to complete. Finally, the cell line can change its responsiveness to cytokine over time.
AND GENOMIC TECHNOLOGIES
Bi o Feature Viral Binding Proteins as Antibody Surrogates in Immunoassays of Cytokines
Immunoassays
Antibody-based assays [ELISA and radioimmunoassay (RIA)] sold as kits are currently the standard for quantification of most cytokines, but the long assay time hinders their utility in the clinical setting. Recent developments in microfluorimetry and microfluidics have permitted the simultaneous detection of multiple analytes using antibody-based capture and reporter molecules (40) . Although this approach has shortened the assay development time, it is still too long to provide widespread benefit in the diagnosis and treatment of infections in the acute care setting.
Conventional antibodies. The rapidity and sensitivity of antibody-based assays are limited by the affinity of the antibody for its cognate antigen, although recent advances using "singlechain Fv fragments" and the manipulation of antigen specificities by molecular techniques may be helpful in addressing these problems (7, 13, 24, 27, 29, 56, 58) . Antibody-based assays still have a number of drawbacks. Currently, the production of specific anti-cytokine antibodies is expensive because of the requirement for animals or tissue culture to produce these molecules; production runs suffer from batch-tobatch variation; and the initial product is contaminated with naturally occurring antibodies that require absorption to render the reagents specific. These conditions apply to both monoclonal and polyclonal antibodies irrespective of whether they are generated in vivo in animals or in vitro in bioreactors.
While specific antibodies for cytokines are expensive to produce, they still provide an advantage for quantification over labor-intensive cellular bioassays. Immunoassays have equal sensitivity (pg/mL), are faster and less expensive to perform, and require less specialized equipment and personnel. Despite these advantages, recent international collaborative studies by the World Health Organization (WHO) and others have shown that current ELISA and RIA assays for tumor necrosis factor (TNF)-α , interleukin (IL)-2, and IL-6 lacked the desired accuracy and reproducibility (15, 31) . These studies noted differences, often exceeding 100-fold, between cytokine levels measured by different immunoassay procedures for the same sample (15, 31) . Another study using an IL-1 ELISA demonstrated that over 90% of the samples testing positive (>100 pg/mL) were false when tested by bioassay (22) .
False positives were measured also in samples sent to a reference laboratory for analysis. The false-positive reaction was blocked by the addition of normal mouse serum to the test samples, indicating the presence of human antimouse IgG heterophilic antibodies reacting with the immobilized mouse anti-cytokine antibody (22) . Also, both α -2 macroglobulin and albumin have been shown to exhibit profound effects on the measurement of cytokine levels by commercial ELISA kits for IL-β , IL-2, IL-4, IL-6, and TNF-α (25) . The effects of these and other potentially interfering plasma proteins may vary with kits from different suppliers and could account for some or all of the problems identified in the WHO studies. Because all of these kits use antibodies that differ significantly in affinity and specificity between lots and suppliers, they will continue to suffer from inconsistencies in assay accuracy that are due to their primary detection reagents. The problems associated with antibody-based cytokine quantitation assays were reminiscent of the initial problems that were encountered in screening monoclonal antibodies using rabbit antimouse immunoglobulin reagents. In the mouse monoclonal antibody system, the ability to distinguish between positive and negative hybridoma supernatants in screening assays proved difficult, and the results were not always reproducible from day to day. These technical limitations were overcome with the introduction of protein A, a high-affinity bacterial immunoglobulin-binding protein that has the ability to bind to the Fc region of many species and subclasses of mammalian IgG immunoglobulins (11) . The availability of protein A proved to be critical for the early development of screening methods to identify monoclonal antibody-producing hybridomas; however, studies indicated that protein A was not ideal since it failed to react with all isotypes and subclasses of mouse immunoglobulin (11) . Subsequent studies led to the identification of a second generation of bacterial IgGbinding proteins, like streptococcal protein G (42, 43) , that could extend the range of reactive monoclonal antibodies that could be identified. These reagents also prove to be of great value, once immobilized, for the subsequent purification of monoclonal antibodies generated in vivo or in vitro (9,10). Synthetic antibodies. Synthetic antibodies were constructed through linking repertoires of antibody variable heavy and light chain domains. These single-chain Fv fragments were expressed as fusions with a bacterial phage coat protein, permitting the display of a library of single-chain Fv fragments on the surface of phage as well as the isolation of defined binding activities and the genes responsible (57) . Using this approach, phage repertoires were constructed that contain 10 7 to greater than 10 10 phage clones and were used to isolate single-chain Fv fragments against a variety of antigens. The initial binding affinities of these single-chain Fv fragments were only moderate (10 5 -10 6 M -1 ) but in certain cases could be increased to nanomolar and even picomolar levels through targeted mutagenesis. Because the singlechain Fv fragments are produced in bacterial expression systems, they will be less costly to produce and purify than conventional antibodies. Thus, single-chain Fv fragments with affinities in the nanomolar range and high specificity for the target antigen are an alternative to polyclonal and monoclonal 
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antibodies as reagents for the development of immunoassays for cytokines.
The ability to produce antibody-like molecules in E. coli using phage display technology and to humanize the constant regions has made enormous technical advances within the past five years (13, 33, 58) . The potential to design and manipulate the affinity of these reagents for any novel specificity (e.g., a unique tumor specific antigen) and to produce the products in a wellcontrolled fermentation system offers great promise for therapeutics and diagnostics in a variety of human diseases (7, 29, 38, 56) . The capability to produce these key reagents without the use of an animal intermediate has great practical value in addressing the issue of batch-to-batch variability and cost.
The very precise epitope recognition by antibodies is, however, a basis for limiting their use for diagnostic applications involving large outbred populations with minor allelic polymorphisms in the target protein. As noted earlier in the WHO tests, the existing panel of cytokine-specific monoclonal antibodies has not performed with the precision and reproducibility required in routine clinical diagnostic assays (15, 31) . These findings are reminiscent of other studies using monoclonal antibodies to human IgG subclasses, which demonstrated similar problems in another WHO-organized comparative study (26) . In this case, some of the problems could be mapped to differences in allotypes of immunoglobulins. This precise specificity was also observed with certain bacterial immunoglobulin-binding proteins (20) ; however, some sources of bacterial IgG-binding proteins demonstrate pan-selectivity for all allotypes of given human IgG subclasses tested (28) .
Thus, while antibody reagents generated by a combination of phage display technology, the use of mutagenesis strategies for affinity maturation, and expression in vitro are all practical, the specificity of the resulting reagent may be too narrow to act effectively as cytokine binding reagents across diverse human populations.
SPECIFIC PATHOGEN-ENCODED CAPTURE/TARGETED RECEP -TOR ACTIVITIES (SPECTRA) AS ANTIBODY MIMICS
Many pathogens have been reported to encode high-affinity binding proteins for cytokines and other key signaling molecules of the host innate and acquired immune system. These molecules are presumably the result of a continuing evolution of the interaction between the host defenses of animals and the virulence strategies of pathogens. Thus, within the genomes of 
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AND GENOMIC TECHNOLOGIES pathogens, we could expect to find the coding sequences for binding proteins, mediators, and/or mimics that disrupt the normal regulation and/or activity of the most critical pathways of the acquired or innate immune responses.
In the context of SPECTRA, the genomes of pathogens would be analogous to the immune splenocytes used to generate monoclonal antibodies. For example, to isolate a binding protein for IL-12, extracts of wild-type pathogens or a library of genes prepared from chromosomal DNA of pathogens would be screened for activities that interfere in an IL-12 immunoassay, bioassay, or binding assay. A positive result would indicate the potential presence of the desired binding activity encoded within the chromosomal DNA of the tested pathogen. This step is equivalent to the initial screening step in a hybridoma fusion, which is followed by an analogous cloning step to identify a hybridoma clone (i.e., identifying the gene expressing the desired activity).
In the SPECTRA screening strategy, the colony expressing a gene encoding the desired activity would be identified Table 2 . Virus-Encoded Cytokine/Chemokine-Binding Proteins and characterized. Standard screening assays to identify a specific functional gene product are common in combinational chemistry, phage display, and monoclonal antibody technology. Once a positive clone is identified, it is then a relatively simple matter to obtain the gene sequence and express large quantities of the product using standard genetic engineering strategies. If a functional recombinant protein can be expressed that retains the desired specificity, then it is practical to develop a range of assays and purification procedures based on the protein's binding characteristics.
The ability to manipulate the sequence to increase or decrease affinity for a given application is also practical. Like antibodies, pathogen-binding protein genes can be manipulated to increase binding affinity by random or targeted mutagenesis and selection for products with higher affinity. This procedure would be equivalent to affinity maturation that is associated with somatic mutations in B cells. Also, through genetic engineering strategies, active domains can be identified and duplicated to potentially increase affinity and/or to remove undesirable crossreactivities. This approach is well established for the streptococcal IgGbinding molecule, protein G (41) .
Based on the parallels with protein A and protein G, we decided to evaluate pathogen-encoded cytokine-binding proteins as an alternative method to quantify cytokines. The rationale was that high-affinity viral cytokine-binding proteins could be used in place of a specific antibody in capture-based immunoassay formats (i.e., act in an analogous manner to the second antibody role fulfilled by protein A or protein G in monoclonal antibody screening). Table 2 summarizes the known virus-encoded cytokine-binding proteins. It is of interest to note that as a genus the orthopoxviruses encode at least three distinct TNF-binding proteins as well as binding proteins for chemokines, IL-18, IL-1 β , and interferons (IFNs). The proteins are secretory homologs of cellular receptors and cytokine-binding proteins that block cytokine action extracellularly before receptor engagement. One of the important features of a number of the binding proteins is their ability to bind cytokines (i.e., IL-18, TNF, IFN-γ , and chemokines) from closely related species. This suggests that the viral binding proteins are recognizing a general molecular shape of the target ligand. In the development of cytokine assays, this "plastic" specificity is a major advantage over monoclonal antibodies or singlechain Fv fragments whose affinity for ligand can be affected by intra-or interspecies genetic polymorphisms.
Each of these viral binding proteins has potential for the measurement of its cognate ligand. IL-1 βand TNF are important mediators of septic shock, and the IFNs can be important indicators of the progression or recovery from diseases and are used therapeutically as well. The availability of sensitive, rapid assays for these molecules would be beneficial. Importantly, the extremely high affinity of the viral cytokine-binding proteins for their ligands suggests that their use as capture and/or detection reagents in immunoassays may result in improved sensitivity compared to antibody-based assays. While the potential for the use of pathogen-binding proteins as antibody mimics is theoretically practical, to date there have been no published examples of their use for quantitative assays. To ensure that these reagents can be of utility in immunoassay-like formats, we evaluated the ability of a poxvirus IFN-γ binding protein to act as a capture reagent in an assay to measure both human and mouse IFN-γ .
Measurement of IFN-γ by an Assay Based on a Pathogen-Encoded Binding Protein
An IFN-γ binding protein is found in a range of poxviruses and is probably the best-studied cytokine-binding protein (4, (35) (36) (37) 55) . For this reason and the fact that IFN-γ is a prototypic Th1 cytokine whose plasma levels are predictive of a number of disease states (44) , this protein would be a good candidate as the selective binding reagent for measuring IFN-γ in clinical samples.
To evaluate the use of the viral IFN-γ binding protein in place of an anti-IFN-γ antibody in immunoassays, increasing concentrations of the binding protein were immobilized onto wells of a microplate. Increasing concentrations of a biotinylated preparation of mouse IFN-γ was added to each well in a checkerboard manner, and bound mouse IFN-γ was detected using a streptavidin-enzyme conjugate reporter system. Figure  1 presents the results of a representative experiment using this checkerboard strategy. This experiment demonstrates that the IFN -γ binding protein can act as a capture reagent for fluid phase mouse IFN-γ and that saturable binding can be achieved. When a similar series of studies were carried out using human IFN-γ , a similar pattern of reactivity was observed (data not shown).
To compare the efficiency of the viral IFN-γ binding protein with the currently used capture reagent, an antibody specific for mouse IFN-γ , a similar experiment was performed using a commercially available goat polyclonal anti-mouse IFN-γneutralizing antibody as the capture reagent. The antibody was immobilized onto a microplate at varying concentrations, and binding of biotinylated mouse IFN-γ was measured. The results presented in Figure 1B showed binding of the tracer under the identical experimental conditions used to generate the data for the IFN-γ binding protein shown in Figure  1A . A comparison of the results in Figure 1, A and B, shows the antibody capture reagent did not result in saturable binding, while this could be achieved using the viral binding protein.
In the next series of studies, the ability of unlabeled mouse or human IFN-γ to compete for binding of biotinylated IFN-γ was tested in an ELISA format using the viral IFN-γ binding protein as the capture reagent. Fluid-phase IFN-γ from either human or mouse caused dose-dependent inhibition of binding of the mouse IFN-γtracer (Figure 2) . These results indicate that the viral IFN-γ binding protein can act as a highaffinity antibody mimic and that this assay system could detect fluid-phase mouse IFN-γin the low nanogram to high picogram range.
Since, as noted earlier, a key problem in conventional ELISA was interference from major plasma proteins (e.g., albumin); these experiments were repeated using human plasma to which known quantities of human IFN-γ were added. The results presented in Figure  3 demonstrated that the inhibition of binding of biotinylated mouse IFN-γ tracer to the viral IFN-γ binding protein was unaffected by the presence of human plasma. Note that the endogenous level of IFN-γin the pooled human plasma sample was below the level of detection in this assay (Figure 3) .
Taken together, these results indicate that the viral binding protein can be immobilized without loss of function and can act as a specific capture reagent in an ELISA. These studies support the theoretical predictions that a viral binding protein can effectively substitute for an antibody in assays to detect IFN-γ . Indeed, the higher affinity of the binding protein has the potential to increase the sensitivity and speed of assays for the inflammatory cytokine, IFN-γ .
Based on these assay studies using Figure 4 can be utilized to purify cytokines from complex mixtures. This general strategy could also be used to selectively precipitate cytokines from biological samples to address fundamental basic research questions of the distribution of cytokines in different secretions or extracellular fluids.
RAPID CYTOKINE DETECTION ASSAYS
There is a clear need for rapid, sensitive, and reproducible cytokine detection assays for clinical samples. Thus, an evaluation of selective capture reagents that can be used to develop such assays is warranted. Traditionally, the choice of capture reagent has focused F igure 5. Schematic representation of protein chip-based profiling of cytokines using a mass spectral read out. Immobilized cytokine capture reagents [e.g., specific viral binding proteins (bp), monoclonal antibodies, single-chain antibodies, etc.] are briefly incubated with a patient specimen, washed with deionized water, and overlaid with an energy-absorbing molecule. Each spot is then vaporized by a laser, and the bound "ligands" analyzed by time-of-flight in a matrix-assisted laser desorption/ionization-mass spectrometer instrument. The molecular weight and signal strength of the detected molecules are compared to a series of cytokine standards. The levels of individual cytokines detected in the specimen are then scored as elevated ↑ , depressed ↓ , or normal -.
on antibodies or antibody-derived molecules; however, based on the studies described above, pathogen-binding proteins with selective recognition properties for cytokines merit further consideration. The key requirement for a capture reagent is a high degree of specificity that permits rapid binding of the targeted cytokine and a slow off-rate of bound cytokine and specific binding of polymorphic variants. Table 3 summarizes the general characteristics of different classes of currently available cytokine capture reagents. A comparison of the properties of these reagents indicates that the pathogen binding proteins merit further evaluation as a new class of specific binding reagents for rapid cytokine assay development.
FUTURE DIRECTIONS
The value of cytokine profiling in diagnosing and monitoring disease progression is now beginning to be elucidated from basic studies in both mouse models and human clinical research protocols. It is clear that in disease states cytokine profiles are dynamic in both quantity and complexity of the signaling molecules. This necessitates that rapid assays for detection of cytokines in conditions like septic shock be available to help the physician implement the appropriate treatment protocol. Furthermore, given the cascade nature of cytokine responses, the ability to monitor rapidly (<45 min) the actual cytokine profile for patients undergoing cytokine therapy, for such conditions as cancer or autoimmunity, will be essential to minimize toxic effects and maximize therapeutic benefit. Consequently, rapid assays that can provide cytokine profiles and at least semi-quantitative data will be extremely beneficial.
The existence of naturally occurring surrogate antibodies or binding proteins encoded within a variety of different viral genomes offer high affinity and selective binding properties that are not as sensitive to polymorphic variations in cytokines and other signaling molecules that are present in outbred populations. The analysis of the structures of known cytokine-binding proteins and other SPECTRA among bacteria, viruses, and fungi combined with data-mining strategies of pathogenic genomes is likely to provide a plethora of useful reagents for monitoring immune mediators. These binding domains could also be exploited in existing antibody framework constructs and be further engineered for enhanced or decreased affinity depending on the desired application.
These pathogen-encoded capture reagents are expected to find applications in combination with other evolving proteomic technologies. For example, viral cytokine-binding proteins bound to protein chips and analysis using a mass spectral read out [MALDI or surface-enhanced laser desorption ionization-time of flight (SELDI-TOF)] ( Figure 5 ) are one anticipated development that will facilitate both a high degree of sensitivity and rapid data generation. This immunoproteomic assay system also has the potential to use the mass spectral profile to monitor the quantity of cytokine present and the conversion of pro-cytokines to their biologically active form, and potentially monitor cytokine fragments that could be used to follow biological regulation of these molecules in vivo.
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